JankovicV1, Main, Exploration, bibRecordById, Pascal:06-0013786

Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

Identifieur interne : 001095 ( Main/Exploration ); précédent : 001094; suivant : 001096

Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

Auteurs : W Ondo [États-Unis] ; R. Fayle [États-Unis] ; F. Atassi [États-Unis] ; Joseph Jankovic [États-Unis]

Source :

Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2005-12.

RBID : ISTEX:A59F319272BB8D4F4894ED4216BEBB9793D54C3A

Descripteurs français

Pascal (Inist)
- Modafinil, Parkinson maladie, Placebo, Somnolence, Système nerveux pathologie.

English descriptors

KwdEn :
- Aged, Benzhydryl Compounds (therapeutic use), Central Nervous System Stimulants (therapeutic use), Disorders of Excessive Somnolence (drug therapy), Disorders of Excessive Somnolence (etiology), Double-Blind Method, EDS, excessive daytime somnolence, ES, Epworth Sleepiness (score), Female, Humans, MSLT, multiple sleep latency test, Male, Middle Aged, Modafinil, Nervous system diseases, PD, Parkinson’s disease, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson’s disease, Placebo, Placebos, Severity of Illness Index, Somnolence, Treatment Outcome, UPDRS, Unified Parkinson’s Disease Rating Scale, excessive daytime sleepiness, modafinil, multiple sleep latency tests.
MESH :
- chemical , therapeutic use : Benzhydryl Compounds, Central Nervous System Stimulants.
- complications : Parkinson Disease.
- drug therapy : Disorders of Excessive Somnolence, Parkinson Disease.
- etiology : Disorders of Excessive Somnolence.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Severity of Illness Index, Treatment Outcome.

Abstract

Background: Excessive daytime somnolence (EDS) commonly complicates Parkinson’s disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions. Method: A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200–400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson’s Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT). Results: Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p = 0.28). MSLT failed to improve with modafinil relative to placebo (−0.16 v −0.70, respectively, p = 0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal. Conclusion: Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.

Url:

DOI: 10.1136/jnnp.2005.065870

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial</title>
<author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name>
</author>
<author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name>
</author>
<author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A59F319272BB8D4F4894ED4216BEBB9793D54C3A</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1136/jnnp.2005.065870</idno>
<idno type="url">https://api.istex.fr/document/A59F319272BB8D4F4894ED4216BEBB9793D54C3A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000610</idno>
<idno type="wicri:Area/Istex/Curation">000610</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C86</idno>
<idno type="wicri:doubleKey">0022-3050:2005:Ondo W:modafinil:for:daytime</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1739456</idno>
<idno type="RBID">PMC:1739456</idno>
<idno type="wicri:Area/Pmc/Corpus">000230</idno>
<idno type="wicri:Area/Pmc/Curation">000230</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000267</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000187</idno>
<idno type="wicri:Area/PubMed/Curation">000187</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000194</idno>
<idno type="wicri:Area/Ncbi/Merge">000103</idno>
<idno type="wicri:Area/Ncbi/Curation">000103</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000103</idno>
<idno type="wicri:doubleKey">0022-3050:2005:Ondo W:modafinil:for:daytime</idno>
<idno type="wicri:Area/Main/Merge">001133</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0013786</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000077</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000089</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000085</idno>
<idno type="wicri:doubleKey">0022-3050:2005:Ondo W:modafinil:for:daytime</idno>
<idno type="wicri:Area/Main/Merge">001205</idno>
<idno type="wicri:Area/Main/Curation">001095</idno>
<idno type="wicri:Area/Main/Exploration">001095</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial</title>
<author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Park Plaza Hospital, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title>
<title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title>
<idno type="ISSN">0022-3050</idno>
<idno type="eISSN">1468-330X</idno>
<imprint><publisher>BMJ Publishing Group Ltd</publisher>
<date type="published" when="2005-12">2005-12</date>
<biblScope unit="volume">76</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1636">1636</biblScope>
</imprint>
<idno type="ISSN">0022-3050</idno>
</series>
<idno type="istex">A59F319272BB8D4F4894ED4216BEBB9793D54C3A</idno>
<idno type="DOI">10.1136/jnnp.2005.065870</idno>
<idno type="href">jnnp-76-1636.pdf</idno>
<idno type="PMID">16291885</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0022-3050</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Benzhydryl Compounds (therapeutic use)</term>
<term>Central Nervous System Stimulants (therapeutic use)</term>
<term>Disorders of Excessive Somnolence (drug therapy)</term>
<term>Disorders of Excessive Somnolence (etiology)</term>
<term>Double-Blind Method</term>
<term>EDS, excessive daytime somnolence</term>
<term>ES, Epworth Sleepiness (score)</term>
<term>Female</term>
<term>Humans</term>
<term>MSLT, multiple sleep latency test</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Modafinil</term>
<term>Nervous system diseases</term>
<term>PD, Parkinson’s disease</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson’s disease</term>
<term>Placebo</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
<term>Somnolence</term>
<term>Treatment Outcome</term>
<term>UPDRS, Unified Parkinson’s Disease Rating Scale</term>
<term>excessive daytime sleepiness</term>
<term>modafinil</term>
<term>multiple sleep latency tests</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzhydryl Compounds</term>
<term>Central Nervous System Stimulants</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Modafinil</term>
<term>Parkinson maladie</term>
<term>Placebo</term>
<term>Somnolence</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Excessive daytime somnolence (EDS) commonly complicates Parkinson’s disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions. Method: A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200–400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson’s Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT). Results: Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p = 0.28). MSLT failed to improve with modafinil relative to placebo (−0.16 v −0.70, respectively, p = 0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal. Conclusion: Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
<settlement><li>Houston</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name>
</region>
<name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name>
<name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name>
<name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001095 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001095 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A59F319272BB8D4F4894ED4216BEBB9793D54C3A
   |texte=   Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial
}}

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024

Serveur d'exploration autour de Joseph Jankovic

Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration autour de Joseph Jankovic
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.